2. Search Result
Search Result
Results for "

stereospecificity

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Biochemical Assay Reagents

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128599
    NMS-P515

    		PARP Cancer
    NMS-P515 is a potent, orally active and stereospecific PARP-1 inhibitor, with a Kd of 16 nM and an IC50 of 27 nM (in Hela cells). Anti-tumor activity .
    NMS-P515
  • HY-148755
    ERX-41

    		Others Cancer
    ERX-41 is an orally active and stereospecific small molecule targeting to lysosomal acid lipase A (LIPA). ERX-41 induces endoplasmic reticulum (ER) stress resulting in cell death, indicating a function independent of LIPA but dependent on its ER localization. ERX-41 involves in a targeted strategy for solid tumors .
    ERX-41
  • HY-116284A
    Methyl β-D-glucopyranoside hemihydrate

    Methyl β-D-glucoside hemihydrate

    		 Others Others
    Methyl β-D-glucopyranoside (Methyl β-D-glucoside) hemihydrate is a hemihydrate compound. Methyl β-D-glucopyranoside hemihydrate less reactive at higher PH. The formation of Methyl β-D-glucopyranoside hemihydrate is stereospecific .
    Methyl β-D-glucopyranoside hemihydrate
  • HY-W353804
    2′-Deoxy-β-L-uridine

    		Nucleoside Antimetabolite/Analog Infection
    2'-Deoxy-β-L-uridine is a nucledside analogue and a specific substrate for the viral enzyme, shows no stereospecificity against herpes simplex 1 (HSV1) thymidine kinase (TK). 2′-Deoxy-β-L-uridine exerts antiviral activity via the interation of 5'-triphosphates with the viral DNA polymerase .
    2′-Deoxy-β-L-uridine
  • HY-P2987
    L-Amino acid oxidase

    		Endogenous Metabolite Metabolic Disease
    L-Amino acid oxidase is a homodimeric proteins containing flavin adenine dinucleotide. L-Amino acid oxidase can catalyze the stereospecific oxidative deamination of L-amino acids to α-keto acids and ammonia .
    L-Amino acid oxidase
  • HY-12483
    SR1664

    		PPAR Metabolic Disease
    SR1664 is a PPARγ antagonist. SR1664 binds to PPARγ and potently inhibits Cdk5-mediated PPARγ phosphorylation (IC50=80 nM; Ki= 28.67 nM) .
    SR1664
  • HY-15314
    Ranirestat
    1 Publications Verification

    AS-3201

    		 Aldose Reductase Neurological Disease Metabolic Disease
    Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC50s of 11 nM and 15 nM for rat lens AR and recombinant human AR, respectively, and a Ki of 0.38 nM for recombinant human AR. Ranirestat has the potential for diabetic sensorimotor polyneuropathy treatment. Ranirestat also has a neuroprotective effect on diabetic retinas .
    Ranirestat

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: